united statesfederal regulators first evaluated last friday the safety and effectivethey exceed the risks of the possible more worrying side effects in that age groupthe analysis was carried out the same day that the food and medicines administration published pfizer data that showed that the vaccine had an efficacy rate of 907 percent to prevent symptomatic covid19 in a clinical trial of children from 5 to 11yearsthe findings could add impulse to the authorization of the fdaof the pediatric dose urgently perhaps from next week opening a new expected phase of the countrys vaccination campaignthe independent committee of agency vaccines experts is scheduled to vote on tuesday about whether to recommend authorizationin an informative document published on the fda website the agency said it had analyzed the hazards of hospitalization death or other serious consequences of covid19 with the risk of myocarditisa rare condition that involves inflammation of heart muscle myocarditis has been linked to pfizerbionntech and modern vaccines especially among young menthe general analysis predicted that the amount of results related to clinically significant covid19 would clearly exceed the number of cases of excessive myocarditis associated with the vaccine the regulators wroteas usual before a vote of the fda advisory committee regulators did not pronounce on whether the new use of a vaccine should be authorizedthe administration of biden has enthusiastically promoting the possibility of a pediatric vaccine and many parents anxiously expect developmentcovid19 cases among children under 18 reached their maximum point in the first week of september when almost a quarter of a million cases were reported